Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does INFLIXIMAB-DYYB Cause Poor venous access? 782 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 782 reports of Poor venous access have been filed in association with INFLIXIMAB-DYYB (ZYMFENTRA). This represents 3.1% of all adverse event reports for INFLIXIMAB-DYYB.

782
Reports of Poor venous access with INFLIXIMAB-DYYB
3.1%
of all INFLIXIMAB-DYYB reports
23
Deaths
286
Hospitalizations

How Dangerous Is Poor venous access From INFLIXIMAB-DYYB?

Of the 782 reports, 23 (2.9%) resulted in death, 286 (36.6%) required hospitalization, and 7 (0.9%) were considered life-threatening.

Is Poor venous access Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for INFLIXIMAB-DYYB. However, 782 reports have been filed with the FAERS database.

What Other Side Effects Does INFLIXIMAB-DYYB Cause?

Off label use (14,256) Condition aggravated (10,275) Intentional product use issue (7,549) Inappropriate schedule of product administration (5,977) Arthralgia (4,615) Drug ineffective (3,112) Fatigue (3,111) Weight increased (2,848) Malaise (2,766) Weight decreased (2,703)

What Other Drugs Cause Poor venous access?

VEDOLIZUMAB (1,043) INFLIXIMAB (917) ECULIZUMAB (555) HUMAN IMMUNOGLOBULIN G (504) NATALIZUMAB (422) RITUXIMAB (299) TOCILIZUMAB (287) METHOTREXATE (257) ABATACEPT (249) IDURSULFASE (175)

Which INFLIXIMAB-DYYB Alternatives Have Lower Poor venous access Risk?

INFLIXIMAB-DYYB vs INFLIXIMAB-QBTX INFLIXIMAB-DYYB vs INFLIXIMAB, RECOMBINANT INFLIXIMAB-DYYB vs INFLUENZA A VIRUS A/CALIFORNIA/7/2009 LIVE ANTIGEN\INFLUENZA A VIRUS A/TEXAS/50/2012 LIVE ANTIGEN\INFLUENZA B VIRUS B/BRISBANE/60/2008 LIVE ANTIGEN\INFLUENZA B VIRUS B/MASSACHUSETTS/2/2012 LIVE ANTIGEN INFLIXIMAB-DYYB vs INFLUENZA VIRUS VACCINE INFLIXIMAB-DYYB vs INFLUENZA VIRUS VACCINE QUADRIVALENT TYPE A+B

Related Pages

INFLIXIMAB-DYYB Full Profile All Poor venous access Reports All Drugs Causing Poor venous access INFLIXIMAB-DYYB Demographics